GlassScriptPhysician profile
Mark Richard Brady
NPI 1992768766
$2,553.02
in general payments reported to CMS, 2019-2025
22 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $25.61 · 2021: $491 · 2022: $464 · 2023: $801 · 2024: $298 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.11 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $681.34 | 2019-2025 | Airsupra, Breztri, Symbicort |
| Glaxosmithkline, LLC. | $660.58 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Actelion Pharmaceuticals US, INC. | $241.76 | 2023-2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $234.67 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $92.03 | 2021-2022 | |
| Novo Nordisk INC | $83.20 | 2021-2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $71.49 | 2022-2023 | |
| Dexcom, INC. | $65.16 | 2019-2023 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $53.84 | 2022-2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.31 | 2019-2023 | Ofev |
| Abbvie INC. | $45.80 | 2021-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $42.67 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $42.24 | 2022-2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $37.27 | 2019 | |
| Mannkind Corporation | $35.20 | 2023 | Afrezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $26.90 | 2019 | |
| Advanced Respiratory, INC | $23.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.34 | 2022 | |
| Insmed, INC. | $16.24 | 2024 | Arikayce |
| Shire North American Group INC | $15.61 | 2019 | |
| Merck Sharp & Dohme LLC | $12.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.